A phase II/III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670a/b in children 5 through 11 years of age.

A phase II/III, randomized, active-comparator, observer-blind, non-inferiority study to demonstrate the immunogenicity and safety of DS-5670a/b (bivalent: original/omicron BA.4-5) in children 5 through 11 years of age.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220399

Enrollment

640

Registered

2022-10-20

Start date

2023-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)

Interventions

A dose of either DS-5670a/b or Comirnaty RTU IM will be intramuscularly administered twice in total to the deltoid muscle of the upper arm.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Children aged 5 to 11 years at the time of informed consent. 2)Subjects who have legal representative signed a written informed consent 3)Subjects who have no history of vaccination against SARS-CoV-2 at the time of consent. 4)Subjects who are willing and able to comply with all scheduled requirements including medical examinations, laboratory tests, and report any symptoms. (possibly filed by legal representative )

Exclusion criteria

Exclusion criteria: 1)Subjects who have a history of seizure or epilepsy due to vaccination. 2)Subjects who have a history of myocarditis or pericarditis 3))Subjects who have had a positive result of SARS-CoV-2 infection test or diagnosed as SARS-CoV-2 infection by medical attention within three months of consent 4)Subjects who have suggestive symptoms of SARS-CoV-2 infection (respiratory symptoms, headache, malaise, olfactory disturbance, taste disturbance, pharyngalgia etc.) at the time of consent. 5)Subjects who have a positive result of SARS-CoV-2 antigen test at the time of eligibility assessment. 6)Subjects who have a history of anaphylaxis or severe allergy to food, pharmaceuticals, cosmetics, vaccination, etc.

Design outcomes

Primary

Measure	Time frame
GMT of blood neutralizing activity against SARS-CoV-2 (Omicron strain BA.5) and seroresponse rate at 4 weeks after the second study drug administration	—

Secondary

Measure	Time frame
Efficacy - Geometric mean fold rise (GMFR) of blood neutralizing activity against SARS-CoV-2 (Omicron strain BA.5) at 4 weeks after the second study drug administration - GMT, seroresponse rate and GMFR of blood neutralizing activity against SARS-CoV-2(original strain) at 4 weeks after the second study drug administration - Incidence of COVID-19 for 52 weeks after the second study drug administration Safety Solicited adverse events (injection site and systemic), Unsolicited adverse events, Serious adverse events, Laboratory values for 28 days after the second study drug administration	—

Measure

Time frame

Efficacy - Geometric mean fold rise (GMFR) of blood neutralizing activity against SARS-CoV-2 (Omicron strain BA.5) at 4 weeks after the second study drug administration - GMT, seroresponse rate and GMFR of blood neutralizing activity against SARS-CoV-2(original strain) at 4 weeks after the second study drug administration - Incidence of COVID-19 for 52 weeks after the second study drug administration Safety Solicited adverse events (injection site and systemic), Unsolicited adverse events, Serious adverse events, Laboratory values for 28 days after the second study drug administration

—

Contacts

Public ContactContact for Clinical Trial Information

DAIICHI SANKYO Co.,Ltd.

dsclinicaltrial@daiichisankyo.co.jp+81-3-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026